但是,ABC型DLBCL对BTK抑制剂反应的分子机制,尤其是MCD型DLBCL患者表现出的如此特殊的反应的原因仍未可知。 近日,来自美国国立卫生研究院的Louis M.Staudt团队和德国法兰克福大学的Thomas Oellerich团队在Cancer Cell上在线发表题为Response to Br...
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.The article reviews a study on any activity of bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) in patients with relapsed/refractory B-cell malignancies ...
深入研究「Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer」主題。共同形成了獨特的指紋。 Ovarian Cancer Medicine and Dentistry 100% Ibrutinib Medicine and Dentistry 100% Bruton Tyrosine Kinase Inhibitor Medicine and Dentistry 100% Ovary C...
Barrientos J, Rai K. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013; 54 :1817–1820.Barrientos J, Rai K. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in ...
Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget. 2015;6:13255–13268. Article PubMed PubMed Central Google Scholar Yue C, Niu M, Shan QQ, Zhou T, Tu Y, Xie P, et al. High expression of Bruton’s tyrosine kinase (BTK) is...
H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88–94 (2013). Article CAS PubMed Google Scholar O'Brien, S. et al. Ibrutinib as initial therapy for elderly patients ...
In B cells, the key member of this kinase family is Bruton tyrosine kinase (BTK), which is mutated in X-linked agammaglobulinemia. Ibrutinib is a BTK inhibitor that has shown promise in the treatment of B-cell malignancies19; such inhibitors may also be useful in the treatment of ...
Bruton’s tyrosine kinase (BTK) inhibitors, such as ibrutinib, zanubrutinib, and acalabrutinib, are used to treat non-Hodgkin lymphoma, among other hematologic malignancies and inflammatory diseases. BTK inhibitors are associated with multiple dermatologic complications, including edema, which has not...
21. Arnold D, Montalban X, Martin E, Hyvert Y, Tomic D.Effects of evobrutinib, a Bruton’s tyrosine kinase inhibitor, on slowly expanding lesions: an emerging imaging marker of chronic tissue loss in multiple sclerosis. Presented at: European Congress on Treatment and Research in Multiple Sc...
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013;54(11):2385–91. : 10.3109/10428194.2013.777837 .Burger, J.A. & Buggy, J.J. ( 2013 ) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) . Leukemia & Lymphoma , 54 , 2385 – 2391 ....